Quantitative effect of Atorvastatin on size and content of non-calcified plaques of coronary arteries 1 year after Atorvastatin treatment by multislice computed tomography

Uehara, Masae; Funabashi, Nobusada; Mikami, Yoko; Shiina, Yumi; Nakamura, Koki; Komuro, Issei

doi:10.1016/j.ijcard.2007.07.013

Cited by 31 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a trend toward LDL levels being related to noncalcified plaque but not the calcified portion. CAC scores did not change [13].…”

Section: Recent Noncontrolled Trialsmentioning

confidence: 85%

“…Because it was observational and not placebo controlled, no conclusions can be drawn. Using MDCT technology, Uehara et al [13] evaluated 21 patients with calcified and noncalcified plaque treated with 10 mg/d of atorvastatin. This also was an observational study, with atorvastatin added after a baseline scan and then a followup scan performed after 1 year.…”

Section: Recent Noncontrolled Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Does Statin Therapy Affect the Progression of Atherosclerosis Measured by a Coronary Calcium Score?

Gill

2010

Curr Atheroscler Rep

View full text Add to dashboard Cite

Coronary atherosclerosis is a leading cause of death in the United States and worldwide, accounting for close to 1 million deaths annually in the United States alone. The evaluation of coronary disease by CT-derived calcium scores is a rapidly evolving field of medical imaging. Furthermore, until recently, whether or not regression or progression of coronary disease could accurately be assessed by coronary calcium scores had been a question of considerable debate among experts in this field. If the medical treatment of coronary artery disease by statin pharmacotherapy could be accurately assessed by coronary calcium scoring, this would take much of the current guess work out of statin pharmacotherapy. Initial retrospective studies and observational data suggested that statin treatment resulted in reduction of coronary calcium. More recently, five randomized controlled trials have demonstrated that not only does statin treatment not reduce coronary calcium, but in fact, the progression of coronary calcium by CT scanning is indistinguishable from placebo treatment.

show abstract

“…There was a trend toward LDL levels being related to noncalcified plaque but not the calcified portion. CAC scores did not change [13].…”

Section: Recent Noncontrolled Trialsmentioning

confidence: 85%

Section: Recent Noncontrolled Trialsmentioning

confidence: 99%

Does Statin Therapy Affect the Progression of Atherosclerosis Measured by a Coronary Calcium Score?

Gill

2010

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

“…Supporting the present finding, Uehara et al have previously demonstrated that 16-slice MDCT was able to non-invasively detect changes in plaque content after atorvastatin treatment in patients with stable coronary artery disease. 29 In that study, mean CT attenuation value of non-calcified plaque was significantly increased from 55 HU to 62 HU after atorvastatin treatment. And Pflederer et al also reported that, compared between ACS patients and stable angina patients, the mean and minimum CT attenuation value of culprit coronary plaque are significantly lower in ACS patients.…”

Section: Discussionmentioning

confidence: 74%

Intensive Lipid-Lowering Therapy With Rosuvastatin Stabilizes Lipid-Rich Coronary Plaques - Evaluation Using Dual-Source Computed Tomography -

Soeda

Uemura

Okayama

et al. 2011

Circ J

View full text Add to dashboard Cite

Background: Clinical studies using invasive modalities have reported that statin therapy stabilizes coronary plaque vulnerability. The serial changes of lipid-rich coronary plaques (LRCPs) during rosuvastatin treatment were evaluated non-invasively in patients with acute coronary syndrome (ACS) using dual-source computed tomography (DSCT). Methods and Results:A total of 11 consecutive ACS patients, and 13 LRCPs were serially evaluated on DSCT before and 24 weeks after rosuvastatin treatment. Compared with the baseline, there was no change in post-treatment minimal lumen diameter, lumen volume, or longitudinal length of LRCPs. By contrast, the ratio of lipid core volume to plaque volume significantly decreased from 48.0±9.9% to 43.7±10.6% (P=0.04), and plaque volume decreased from 144.5±85.5 mm 3 to 119.8±78.0 mm 3 (P=0.07). The remodeling index of target LRCPs significantly decreased from 1.16±0.10 to 1.06±0.12 (P=0.02). Percent reduction of plaque volume was significantly greater in patients with a lower ratio of low-density lipoprotein to high-density lipoprotein (L/H ratio ≤1.5) at follow-up than patients with higher L/H ratio (>1.5; median -31.7% vs. -6.8%, P=0.03). Conclusions:Rosuvastatin therapy reduced the volume of lipid cores and LRCPs and increased the CT attenuation value of LRCPs. DSCT is an effective modality for the non-invasive evaluation of LRCPs in patients with ACS. (Circ J 2011; 75: 2621 - 2627

show abstract

“…Lehman et al (26) observed that a number of cardiovascular risk factors and smoking were independently associated with plaque progression. Uehara et al (30) reported that LDL cholesterol level may be an important factor in decreasing non-calcified plaque area. In contrast, Hoffmann et al (31) found that cardiac risk factors have no significant effect on the plaque growth rate, unlike statin dosage which has a direct effect on the growth rate of non-calcified plaque.…”

Section: Association Between Plaque Volume Changes and Cardiovascularmentioning

confidence: 99%

Serial Changes of Coronary Atherosclerotic Plaque: Assessment with 64-Slice Multi-Detector Computed Tomography

Kim

Kang

Sun

et al. 2013

J Korean Soc Radiol

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose: To evaluate the progression of coronary atherosclerotic plaque during follow-up, and its association with cardiovascular risk factors. Materials and Methods: Fifty-six atherosclerotic patients with plaque were enrolled in this retrospective study. Patient's plaque was detected on repeat 64-slice multidetector CT scans with a mean interval of 25 ± 10 months changes in calcified and noncalcified plaque volumes and cardiovascular risk factors were assessed over time. Absolute and relative changes in plaque volume were compared, and the association between rapid progression and cardiovascular risk factors was determined. Results: Diameter of the stenosis, length, calcified and non-calcified lesion plaque volumes increased significantly on follow-up CT. Absolute and relative annual changes in plaque volumes were significantly greater in non-calcified plaque (median, 22.7 mm 3 , 90.4%) than in calcified plaque (median, 0.7 mm 3 , 0%). Obesity, smoking, hypertension, hypercholesterolemia, and low high-density lipoprotein were significant predictors of progression of non-calcified plaque. Progression of calcified plaque was not associated with any cardiovascular risk factors. Conclusion: Coronary plaque volume increased significantly on follow-up CT. The rate of progression is related to non-calcified plaque than to calcified plaque. Cardiovascular risk factors are independently associated with the rapid progression of non-calcified plaque volume, but not associated with the progression of calcified plaque.

show abstract

Quantitative effect of Atorvastatin on size and content of non-calcified plaques of coronary arteries 1 year after Atorvastatin treatment by multislice computed tomography

Cited by 31 publications

References 20 publications

Does Statin Therapy Affect the Progression of Atherosclerosis Measured by a Coronary Calcium Score?

Does Statin Therapy Affect the Progression of Atherosclerosis Measured by a Coronary Calcium Score?

Intensive Lipid-Lowering Therapy With Rosuvastatin Stabilizes Lipid-Rich Coronary Plaques - Evaluation Using Dual-Source Computed Tomography -

Serial Changes of Coronary Atherosclerotic Plaque: Assessment with 64-Slice Multi-Detector Computed Tomography

Contact Info

Product

Resources

About